Brian Sefton
Brian Sefton has been co-founder, a board member and a part-time advisor at NovoNutrients, a San Francisco-based biotech manufacturer of alt-protein produced from fermentation and CO2 since it was founded in 2017. In 2009, he co-founded research entity Oakbio, from which NovoNutrients evolved, and was its President and CTO.
Sefton was CTO and President at NovoNutrients and also co-CEO and Chief Scientist at Oakbio until 2021 when he became the CEO at San Francisco-based fermentation commercialization startup Sincarne.
Between 2005 and 2011, Sefton was also CEO at pharma research company Pharmadyn, working on drugs development for Alzheimer's Disease, and, for three of those years, was also Managing Partner of Stratsyn, a consultancy specializing in creation, development, management and fund raising for not-for-profit organizations.
Sefton’s earlier posts include: directing nanotechnology commercialization and investment company Nanosig for three years, CEO of Silicon Valley’s Fastlane, a high-profile pioneer in real-time network traffic and security analysis for six years; and, simultaneously, being CEO at Bluebox Communications, developing high-end network security applications and appliances for Fortune 500 companies and the US government.
Sefton holds an MBA from Santa Clara University in California and a bachelor’s degree in biochemistry from the University of California, Berkeley
RELATED INSIGHTS
NovoNutrients: Tackling the dual problems of CO2 emissions and over-fishing
The first to transform CO2 to fish food, NovoNutrients is trialing with industry giants Skretting and Chevron, and will soon raise Series A funding
RECOMMENDED
